Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
Jazz Pharmaceuticals reported mature three-year overall survival data from the Phase 3 HERIZON-GEA-01 trial at ESMO 2026, with Ziihera plus tislelizumab and chemotherapy delivering a median OS of 27.0 months versus 19.6 months with trastuzumab plus chemotherapy, the longest reported in a Phase 3 trial in this setting. Ziihera plus chemotherapy alone also achieved a statistically significant OS benefit, reducing the risk of death by 24% (HR 0.76; P=0.0088), and nearly 40% of patients on the triple regimen were alive at three years regardless of PD-L1 status.
Key figures
- Drug Name
- Ziihera (zanidatamab-hrii)
- Phase Of Trial
- Phase 3
- Patients randomized
- 914
- Median followup months
- 35.3
- Os 36mo triple combination
- 39.8%
- Hazard ratio triple vs control
- 0.65
- Median os ziihera chemo months
- 22.9
- Median os triple combination months
- 27
- Median os trastuzumab control months
- 19.6
- Hazard ratio ziihera chemo vs control
- 0.76
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.